151 related articles for article (PubMed ID: 25806327)
21. Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].
Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Yamamoto N; Nishio M; Ohe Y; Kato T; Takahashi T; Kamada A; Suzukawa K; Omori Y; Enatsu S; Nakagawa K; Tamura T
Lung Cancer; 2019 Jun; 132():157-158. PubMed ID: 31014853
[No Abstract] [Full Text] [Related]
22. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis G; Ziogas DC; Kyriazoglou A; Lykka M; Koutsoukos K; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):143. PubMed ID: 29862232
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetics of Necitumumab in Cancer Patients.
Long A; Chigutsa E; Wallin J
Clin Pharmacokinet; 2017 May; 56(5):505-514. PubMed ID: 27696220
[TBL] [Abstract][Full Text] [Related]
24. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B; Witteveen PO; Ruijter R; Giaccone G; Dontabhaktuni A; Fox F; Katz T; Youssoufian H; Zhu J; Rowinsky EK; Voest EE
Clin Cancer Res; 2010 Mar; 16(6):1915-23. PubMed ID: 20197484
[TBL] [Abstract][Full Text] [Related]
25. NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
Umeweni N; Knight H; McVeigh G
Lancet Oncol; 2016 Nov; 17(11):1483-1484. PubMed ID: 27692477
[No Abstract] [Full Text] [Related]
26. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Langer CJ; Obasaju C; Bunn P; Bonomi P; Gandara D; Hirsch FR; Kim ES; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Socinski MA; Spigel DR; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Dec; 11(12):2066-2081. PubMed ID: 27575423
[TBL] [Abstract][Full Text] [Related]
27. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
28. Necitumumab for patients with non-squamous NSCLC: uninspiring results.
Zhou F; Zhou C
Lancet Oncol; 2015 Mar; 16(3):246-7. PubMed ID: 25701169
[No Abstract] [Full Text] [Related]
29. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Wakelee H; Thatcher N
J Thorac Oncol; 2018 Feb; 13(2):165-183. PubMed ID: 29175116
[TBL] [Abstract][Full Text] [Related]
30. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
Daaboul N; Nicholas G; Laurie SA
Curr Oncol; 2018 Jun; 25(Suppl 1):S77-S85. PubMed ID: 29910650
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
32. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
Suzuki S; Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Suda T
Invest New Drugs; 2016 Aug; 34(4):490-6. PubMed ID: 27279143
[TBL] [Abstract][Full Text] [Related]
33. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the treatment of non-small cell and small cell lung cancer.
Stinchcombe TE
F1000Prime Rep; 2014; 6():117. PubMed ID: 25580271
[TBL] [Abstract][Full Text] [Related]
35. Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.
Yee D
BioDrugs; 2011 Aug; 25(4):271-3. PubMed ID: 21815704
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapies for Lung Cancer.
Stinchcombe TE
Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer.
Song Z; Zhang Y
Arch Med Sci; 2015 Mar; 11(1):164-8. PubMed ID: 25861304
[TBL] [Abstract][Full Text] [Related]
38. Genetic insight and therapeutic targets in squamous-cell lung cancer.
Sos ML; Thomas RK
Oncogene; 2012 Nov; 31(46):4811-4. PubMed ID: 22266863
[TBL] [Abstract][Full Text] [Related]
39. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
40. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
